Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications | Signal Transduction and Targeted Therapy
Balovaptan Archives - CmaxInsight
A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism | Science Translational Medicine
Optimism, confusion greet federal fast track for autism drug
Biomedicines | Free Full-Text | The Biology of Vasopressin
The study design is as explained in Figures 4 and 5. Sal and VPA rats... | Download Scientific Diagram
Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial - The Lancet Psychiatry
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
Balovaptan - Wikipedia
Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in h
Clinical Trial – Autism Spectrum Disorder – Efficacy and Safety of Balovaptan | ForPatients-Roche
A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders - ScienceDirect
Targeting antidiuretic hormone vasopressin shows promise for autism
Biomedicines | Free Full-Text | The Biology of Vasopressin
IJMS | Free Full-Text | Role of Oxytocin and Vasopressin in Neuropsychiatric Disorders: Therapeutic Potential of Agonists and Antagonists
PDF) Balovaptan
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications | Signal Transduction and Targeted Therapy
A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder | SpringerLink
Biomedicines | Free Full-Text | The Biology of Vasopressin
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
Balovaptan and Autism Spectrum Disorder
Decoding microRNAs in autism spectrum disorder: Molecular Therapy - Nucleic Acids
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
Upcoming events – Roche aims to change autism and Ocular awaits pivotal results | Evaluate
